Literature DB >> 10836479

Study of intragastric administration of doxycycline: pharmacokinetics including body fluid, endometrial and minimum inhibitory concentrations.

J E Bryant1, M P Brown, R R Gronwall, K A Merritt.   

Abstract

The objectives of this study were to determine the pharmacokinetics and tissue concentrations of doxycycline after repeated intragastric administration, and to determine the minimum inhibitory concentrations (MIC) for equine pathogenic bacteria. In experiment 1, 2 mares received a single intragastric dose of doxycycline hyclate (3 mg/kg bwt). Mean peak serum concentration was 0.22 microg/ml 1 h postadministration. In experiment 2, 5 doses of doxycycline hyclate (10 mg/kg bwt), dissolved in water, were administered to each of 6 mares via nasogastric tube at 12 h intervals. The mean +/- s.e. peak serum doxycycline concentration was 0.32+/-0.16 microg/ml 1 h after the first dose and 0.42+/-0.05 microg/ml 2 h after the fifth dose. The mean trough serum concentrations were > 0.16 microg/ml. Highest mean synovial concentration was 0.46+/-0.13 microg/ml and highest mean peritoneal concentration was 0.43+/-0.07 microg/ml, both 2 h after the fifth dose. Highest urine concentration was mean +/- s.e. 145+/-25.4 microg/ml 2 h after the last dose. Highest endometrial concentration was mean +/- s.e. 1.30+/-0.36 microg/ml 3 h after the fifth dose. Doxycycline was not detected in any of the CSF samples. Mean +/- s.e. Vd(area) was 25.3+/-5.0 l/kg and mean t1/2 was 8.7+/-1.6 h. In experiment 3, minimum inhibitory concentrations of doxycycline were determined for 168 equine bacterial culture specimens. The MIC90 was < or = 1.0 microg/ml for Streptococcus zooepidemicus and 0.25 microg/ml for Staphylococcus aureus. Based on drug concentrations achieved in the serum, synovial and peritoneal fluids and endometrial tissues and MIC values determined in the present study, doxycycline at a dose of 10 mg/kg bwt per os every 12 h may be appropriate for the treatment of infections caused by susceptible (MIC < 0.25 microg/ml) gram-positive organisms in horses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836479     DOI: 10.2746/042516400776563608

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  6 in total

1.  Pharmacokinetics and bioavailability of doxycycline in ostriches (Struthio camelus) at two different dose rates.

Authors:  Ehab A Abu-Basha; Nasir M Idkaidek; Tareq M Hantash
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

2.  Borrelia burgdorferi Infection and Lyme Disease in North American Horses: A Consensus Statement.

Authors:  T J Divers; R B Gardner; J E Madigan; S G Witonsky; J J Bertone; E L Swinebroad; S E Schutzer; A L Johnson
Journal:  J Vet Intern Med       Date:  2018-02-22       Impact factor: 3.333

3.  Pharmacokinetic Profile of Doxycycline in Koala Plasma after Weekly Subcutaneous Injections for the Treatment of Chlamydiosis.

Authors:  Chien-Jung Chen; Amber Gillett; Rosemary Booth; Benjamin Kimble; Merran Govendir
Journal:  Animals (Basel)       Date:  2022-01-20       Impact factor: 2.752

4.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

5.  Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses.

Authors:  Heidi Zozaya; Lilia Gutierrez; Maria Josefa Bernad; Hector Sumano
Journal:  Acta Vet Scand       Date:  2013-03-08       Impact factor: 1.695

6.  In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.

Authors:  Sanjie Caol; Thomas Divers; Mark Crisman; Yung-Fu Chang
Journal:  BMC Vet Res       Date:  2017-09-29       Impact factor: 2.741

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.